What early stage breast cancer patients would you give IOeRT?

I think given data from ELIOT update (11% LR with electron IORT vs. 2% WBI) and the TARGIT-A update, there is a limited role for IORT as monotherapy at this time, particularly when options like 5 fx PBI and 5 fx WBI are now possible.

The ABS guidelines do not recommend either IORT technique which is...

I completely agree with Dr. @Dr. First Last. The data from RAPID and RTOG 0413 strongly suggest that external beam partial breast irradiation confers long-term control of disease in the breast that is equivalent to whole breast irradiation. In contrast, the long-term data suggest that IORT, with eit...

Have been using the 5 fx approach in the OPAL II Study that @Dr. First Last mentions above. There is a "boost" option that is a SIB with 30/5 and it creates excellent plans with 26/5 to seroma+clips+2cm CTV margin, 30/5 to seroma+clips+1cm CTV margin. The acute toxicity is very, very low. Livi an op...

I personally started to use the UK FAST FORWARD regimen (26 Gy in 5 fractions QD) in 3D conformal APBI. I think we know from the randomized trials that patients receiving APBI usually present with a low risk cancer, a T1N0 ER+, post-menopausal, and very possibly, they don't need a higher PBI dose. I...

I do not use electron IORT since the data from the ELIOT trial is inferior to EBRT.

I use definitive TARGIT-IORT in many of my early stage patients with outcomes as per the TARGIT-A pre-path trial. See BMJ 8-19-2020 publication. It is much easier and more convenient for the patient than external be...